What happened
OpenAI announced it will lead a $15 million seed funding round in Red Queen Bio, a startup focused on preventing malicious actors from using AI to create biological weapons. The investment represents OpenAI's latest effort to support companies working to mitigate AI-related risks. OpenAI CEO Sam Altman and board member Nicole Seligman will receive shares in Red Queen Bio as part of the deal.
Why it matters
- Red Queen Bio will use AI models and traditional laboratory experiments to identify vulnerabilities in biosecurity and develop protective capabilities against AI-enabled biological threats.
- Researchers have warned that the same AI tools used for drug discovery and vaccine design could be misused to engineer biological weapons.
- The investment signals OpenAI's commitment to building ecosystem resilience against AI-related risks, following similar backing of biosecurity software company Valthos.
Key facts
- 1. OpenAI is leading a $15 million seed funding round in Red Queen Bio.
- 2. OpenAI CEO Sam Altman and board member Nicole Seligman will receive shares in the startup as part of the investment deal.
- 3. OpenAI previously backed Valthos, a New York-based biosecurity software company, as part of its broader risk mitigation strategy.
